CONSUMER healthcare company Haleon has announced a five-year fellowship program at the University of Sydney to research the therapeutic role of supplements in managing osteoarthritis symptoms and explore digital technologies to improve mobility.
The fellowship will support a postdoctoral researcher working under osteoarthritis expert, Prof David Hunter.
Hunter said, "this is a disabling disease and collaborating between researchers and manufacturers will drive innovation in management strategies".
Osteoarthritis, affecting over two million Australians and 595 million people globally, is a significant public health issue, particularly among ageing populations.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Oct 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Oct 24
